Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression
Helus Pharma's psilocin-based HLP003 significantly reduced symptoms of major depressive disorder in the adjuvant setting in a Phase 3 trial but was tripped up in the stock market by three serious adverse events.
comments(0)
5-min edit window · permanent after that